1. FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug — Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 — Novo Nordisk's Ozempic wins FDA label boost with CV indication — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Kevin K is a VP

Discussion in 'CSL Behring' started by anonymous, Mar 1, 2019 at 11:50 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Wow. He allegedly has had numerous HR violations. (I saw in action, but have to say alleged). He had numerous marketing mistakes like the Rhophylac Salad campaign that was pulled in about two weeks. I don’t understand this at all. PP is a great leader, why is he allowing dirt to settle at the top.
     

  2. anonymous

    anonymous Guest

    That's a great question. He must have a big blind spot, or he's not really as good as we think. BC and BL are mediocre at best. They wouldn't have those jobs anywhere else.